Form 10-Q Evoke Pharma Inc For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Noble Financial Keeps Evoke Pharma (EVOK) at 'Hold' Following Q2 Numbers; Still Awaiting Development Plans
August 16, 2016 8:43 AM EDTNoble Financial affirms Evoke Pharma (Nasdaq: EVOK) with a Hold rating following Q2 results issued Monday night.
Analyst Nathan Cali noted the following on Tuesday:
Operational costs incrementally lower. August 15th, 2016, reported second quarter financial results; no revenues as expected; SG&A $802,655... MoreEvoke Pharma (EVOK) Tops Q2 EPS by 2c
August 15, 2016 4:35 PM EDTEvoke Pharma (NASDAQ: EVOK) reported Q2 EPS of ($0.41), $0.02 better than the analyst estimate of ($0.43).
As of June 30, 2016, the Company's cash and cash equivalents were approximately $4.1 million.
Dave Gonyer, R.Ph., President and CEO, stated, Following the results of our recently concluded Phase 3 study of Gimoti, our nasally delivered metoclopramide product for the treatment of diabetic gastroparesis in women, we continue to analyze the incoming data to further understand the... More
